Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
TEL TE Connectivity Ltd
BOKF BOK Financial Corp
SMBK SmartFinancial Inc
PRAA PRA Group Inc
FHN First Horizon Corp (Tennessee)
XEL Xcel Energy Inc
XEC Cimarex Energy Co
XCUR Exicure Inc
XBIT XBiotech Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Premarket

Last Trade
Delayed
$6.66
0.16 (2.46%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$6.50
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,595,000

10-day average volume:
34,725,123
3,595,000

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, April 21, 2021
Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization

-- Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the second dose in preventing COVID-19 in those without prior infection -- Demonstrates 70% efficacy against asymptomatic COVID-19 infections...(Globe Newswire)

April 14, 2021
Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that John Paul (J.P.)...(Globe Newswire)

March 29, 2021
Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at...(Globe Newswire)

March 18, 2021
Ocugen Provides Business Update and Full Year 2020 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Ocugen, Inc. ("Ocugen") (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save...(Globe Newswire)

Ocugen Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Ocugen Inc (NASDAQ:OCGN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021 at 8:30 AM Eastern Time. (Accesswire)

March 12, 2021
Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update

Ocugen, Inc.("Ocugen") (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will...(Globe Newswire)

March 08, 2021
Ocugen Inc. to Present at Upcoming March Investor Conferences

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at...(Globe Newswire)

March 03, 2021
Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development...(Globe Newswire)

February 23, 2021
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that on the...(Globe Newswire)

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from...(Thomson Reuters ONE)

February 10, 2021
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock

Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has closed the previously...(Globe Newswire)

February 07, 2021
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has entered into...(Globe Newswire)

February 02, 2021
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN(TM) in the US Market

Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, and Bharat Biotech, a global leader in vaccine...(Globe Newswire)

January 25, 2021
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocugen, Inc. - OCGN

New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc.("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Robert S. Willoughby at...(Newsfile)

SHAREHOLDER ALERT: Investigation of Ocugen Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) complied with federal securities laws. On January 12, 2021, Ocugen announced the...(Newsfile)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.